Can fibroblast growth factor 23 fine-tune therapies for diseases of abnormal mineral ion metabolism?
Razzaque
M Shawkat
MS
Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA 02115, USA. mrazzaque@hms.harvard.edu
D000818:Animals; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000037:antagonists & inhibitors / Q000097:blood* / Q000235:genetics; D020868:Gene Silencing; D006801:Humans; D006961:Hyperparathyroidism / Q000097:blood; D008659:Metabolic Diseases / Q000097:blood* / Q000188:drug therapy / Q000235:genetics; D010760:Phosphorus Metabolism Disorders / Q000097:blood / Q000188:drug therapy / Q000235:genetics; D014807:Vitamin D / Q000097:blood
D014807:Vitamin D; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23